Clinical Scorecard: Advancements in Intranasal Influenza Vaccines: Mechanisms, Platforms, and Progress in Translation

At a Glance

Key Highlights

• Intranasal vaccines can induce both systemic and mucosal immune responses.
• Live-attenuated influenza vaccines (LAIV) are the only licensed intranasal seasonal influenza vaccine.
• Intranasal delivery increases patient compliance and reduces risks associated with needles.
• Next-generation intranasal vaccines aim to improve consistency, safety, and applicability across diverse populations.
• Intranasal vaccines may reduce production and distribution costs and are less dependent on cold-chain maintenance.

Guideline-Based Recommendations

Diagnosis

• Consider seasonal influenza vaccination for at-risk populations.

Management

• Utilize intranasal vaccines to enhance mucosal immunity and reduce transmission.

Monitoring & Follow-up

• Monitor vaccine effectiveness and safety across different populations.

Risks

• Be aware of variable performance in adults and strain-dependent viral fitness.

Patient & Prescribing Data

Individuals eligible for seasonal influenza vaccination, especially children.

Intranasal vaccines may provide broader protection and reduce transmission.

Clinical Best Practices

• Encourage intranasal vaccination to improve compliance, especially in pediatric patients.
• Consider the use of adjuvants and novel delivery platforms to enhance immunogenicity.
• Promote awareness of the advantages of intranasal vaccines over traditional IM vaccines.

References

• Influenza burden statistics
• Intranasal vaccine mechanisms